Abbott Laboratories reports developments across a global healthcare portfolio that includes diagnostics, medical devices, nutritionals and branded generic medicines. Recurring updates cover cardiovascular technologies such as Ultreon coronary imaging, pulsed field ablation and cardiac pacing systems; diabetes and other medical devices; nutritional products; and diagnostic testing.
Abbott news also includes financial results, guidance, product clearances, clinical data presentations, commercial integrations and portfolio changes. Following the completed Exact Sciences acquisition, oncology diagnostics are a recurring theme, including Cologuard, Oncotype DX, Oncodetect, Riskguard and Cancerguard tests for cancer screening, recurrence risk and treatment support.
Abbott (NYSE: ABT) launched "The (Second) Talk" campaign on March 24, 2026, reuniting John Stamos and Jodie Sweetin to encourage colorectal cancer screening for adults 45 and older.
The campaign promotes the FDA-approved Cologuard test as a noninvasive, at-home screening option; a clinical study reports Cologuard Plus detected 95% of colon cancers.
Abbott (NYSE: ABT) completed its acquisition of Exact Sciences on March 23, 2026, making Exact Sciences a wholly owned Abbott subsidiary and ending Exact Sciences' Nasdaq trading on March 20, 2026.
The deal adds a comprehensive cancer screening and precision oncology portfolio — including Cologuard, Oncotype DX, Oncodetect and Cancerguard — and positions Abbott to serve millions more and lead in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segments.
Abbott (NYSE: ABT) expects to close its acquisition of Exact Sciences on March 23, 2026 after receiving all required regulatory clearances. The deal adds cancer screening and precision oncology capabilities, including Cologuard and Oncotype DX, and is expected to contribute ~$3 billion of incremental sales in 2026.
The transaction is projected to accelerate Abbott's 2026 sales growth by ~0.5 percentage points and dilute 2026 adjusted EPS by ~$0.20.
Abbott (NYSE: ABT) reported results from the FreeDM2 randomized controlled trial showing that people with Type 2 diabetes on basal insulin using FreeStyle Libre continuous glucose monitoring (CGM) achieved better glucose control versus fingersticks at four months.
Key findings: HbA1c fell 0.6% (p<0.001) and participants spent ~2.5 more hours/day in the 70–180 mg/dL healthy range (a 10.4% increase). An Italian interventional study of 88 people showed similar benefits at three months.
Abbott (NYSE: ABT) and Real Madrid launched year two of the Abbott Dream Team, a nationwide youth program for 18–19-year-old soccer players offering free selection events, health and nutrition education, and on-field development led by Real Madrid coaches. 16 finalists will receive an all‑expenses‑paid training trip to Madrid and return to lead local health sessions.
Selection events run May–June in Miami, Washington D.C., Houston, Kansas City, Los Angeles and Chicago; participants register at AbbottDreamTeam.com. Marcelo will join as a mentor.
Summary not available.
Exact Sciences (NASDAQ: EXAS) stockholders voted to approve the proposed acquisition by Abbott (NYSE: ABT) at a special meeting held February 20, 2026. Preliminary results showed >99% of votes cast, representing ~67% of outstanding shares as of the January 9, 2026 record date, voted in favor.
Subject to satisfaction or waiver of remaining closing conditions, the transaction is expected to close before the end of the second calendar quarter of 2026. According to the company, each Exact Sciences share will receive $105.00 in cash upon completion, without interest and subject to applicable withholding taxes. Final voting results will be reported on Form 8-K filed with the SEC.
Abbott (NYSE: ABT) declared a quarterly common dividend of $0.63 per share, payable May 15, 2026, to shareholders of record at the close of business April 15, 2026.
This is the 409th consecutive quarterly dividend since 1924 and continues Abbott's streak of increasing dividends for 54 consecutive years; Abbott remains in the S&P 500 Dividend Aristocrats Index.
Abbott (NYSE: ABT) reported late-breaking clinical results (Feb 6, 2026) showing strong safety and efficacy for two AFib ablation devices: the Volt™ Pulsed Field Ablation (PFA) System and the TactiFlex™ Duo Ablation Catheter, Sensor Enabled.
Key highlights: Volt showed 84.2% freedom from rhythm recurrence in PAF and ~68% in persistent AF at 12 months, 6% repeat ablation rate, and marked AFEQT QoL improvements. TactiFlex Duo showed 81% freedom from recurrence in PAF at six months and supported CE Mark approval.
Abbott (NYSE: ABT) reported fourth-quarter 2025 and full-year results and issued 2026 guidance. 4Q25 GAAP diluted EPS $1.01; adjusted diluted EPS $1.50 (+12%). Full-year 2025 GAAP diluted EPS $3.72; adjusted diluted EPS $5.15 (+10%). Full-year 2025 sales were $44.3 billion (+5.7% reported; +5.5% organic). Abbott projects 2026 organic sales +6.5% to +7.5% and adjusted diluted EPS $5.55–$5.80 (midpoint ≈ +10%). Company expects Exact Sciences acquisition to close in Q2 2026 and noted FDA approval for the Volt PFA System and CE Mark for TactiFlex Duo.